SECAUCUS, N.J. and SOUTH SAN FRANCISCO, Calif., Nov. 22 /PRNewswire-FirstCall/ -- AlgoRx Pharmaceuticals, Inc. and Corgentech Inc. , today announced that John P. McLaughlin, Corgentech's chief executive officer, will present at the Lazard Capital Markets 2005 Life Sciences Conference on November 30, 2005 at 11:00 a.m. EST in New York, NY.
To access the live webcast or the subsequent archived recording, log on to www.corgentech.com and go to the Investors page, and click on Webcasts. Please connect to Corgentech's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
Corgentech and private company, AlgoRx Pharmaceuticals, Inc., recently announced that they have signed a definitive agreement to merge and create a late-stage company that will be focused on developing and commercializing products for pain management and inflammation.
AlgoRx is a private, emerging pharmaceutical company focused on developing and commercializing a diversified portfolio of pharmaceutical product candidates to address pain, a large and under-served market. AlgoRx's portfolio of pain management drug candidates includes ALGRX 3268, which has completed Phase 3 clinical trials, ALGRX 4975, which is in Phase 2 clinical trials, and ALGRX 1207, which is soon to enter the clinic. AlgoRx is based in Secaucus, NJ. For more information on the company and its technologies, please visit www.algorx.com.
Corgentech is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for significant unmet medical needs. Corgentech is based in South San Francisco, CA. For more information on the company and its technologies, please visit www.corgentech.com.
CONTACT: Jennifer Cook Williams, Senior Director, Investor Relations ofCorgentech Inc., +1-650-624-9600, or firstname.lastname@example.org